FDA clears Cardinal's Lymphoseek for pediatric use

2021 06 11 15 46 2674 Injection Syringe 400

Cardinal Health announced that its Lymphoseek radiopharmaceutical has been approved for pediatric use by the U.S. Food and Drug Administration (FDA).

This comes after a clinical trial showed the radiopharmaceutical was deemed "safe and effective" for patients ages one month and older.

In addition to adult use, Lymphoseek provides lymph node identification in pediatric patients with melanoma, rhabdomyosarcoma (RMS), or other types of solid tumors. The approval will offer physicians, oncologists, and nuclear medicine specialists an option to enhance lymphatic mapping and guide sentinel lymph node biopsies in pediatric melanoma cases.

Page 1 of 436
Next Page